ArticleCureus2025
Serum Tryptophan and Kynurenine/Tryptophan Ratio as Markers of Depressive Symptoms in Chronic Obstructive Pulmonary Disease (COPD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Depression is a common comorbidity in patients with chronic obstructive pulmonary disease (COPD). Given the involvement of the tryptophan-kynurenine pathway in depression, this study aimed to investigate the potential clinical value of the serum markers of tryptophan-kynurenine metabolism in COPD-related depressive symptoms. Methods A comparative cross-sectional study was designed. The serum levels of tryptophan and kynurenine were measured by liquid chromatography-mass spectrometry in consecutive adult patients with severe COPD. The tryptophan, kynurenine, and kynurenine-to-tryptophan ratio (KTR) were investigated as potential markers for depressive symptoms, which were classified by the six-item Hamilton Depression subscale (HDS-6). The associations of tryptophan-kynurenine pathway markers with depressive symptoms were assessed using Spearman's correlation and logistic regression models. Results Among the included 102 patients with COPD, 44 (43.1%) had depressive symptoms. Compared to the controls, the patients with depressive symptoms had lower serum levels of tryptophan and a higher kynurenine-to-tryptophan ratio (KTR). The severity of depressive symptoms, as measured by the HDS-6 score, showed a significant negative correlation with tryptophan levels (ρ=-0.478, p<0.001) and a positive correlation with KTR (ρ=0.613, p<0.001). In multivariate logistic analyses, higher serum tryptophan quartiles were associated with a decreasing risk of depressive symptoms, while higher KTR quartiles were associated with an increasing risk (p for trend <0.001 for both). Conclusion In this cohort of COPD patients, lower serum tryptophan and a higher kynurenine-to-tryptophan ratio (KTR) were significantly associated with the presence and severity of depressive symptoms. These findings nominate serum tryptophan and KTR as potential biomarkers for assessing depressive symptoms in COPD, which could improve diagnostic accuracy and guide treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.